Oncolytic virotherapy using herpes simplex virus: how far have we come?

Nicolas A. S. Sokolowski; Helen Rizos; Russell J. Diefenbach

doi:10.2147/OV.S66086

Oncolytic virotherapy using herpes simplex virus: how far have we come?

Nicolas A. S. Sokolowski, Helen Rizos, Russell J. Diefenbach

Research output: Contribution to journal › Review article › peer-review

112 Downloads (Pure)

Abstract

Oncolytic virotherapy exploits the properties of human viruses to naturally cause cytolysis of cancer cells. The human pathogen herpes simplex virus (HSV) has proven particularly amenable for use in oncolytic virotherapy. The relative safety of HSV coupled with extensive knowledge on how HSV interacts with the host has provided a platform for manipulating HSV to enhance the targeting and killing of human cancer cells. This has culminated in the approval of talimogene laherparepvec for the treatment of melanoma. This review focuses on the development of HSV as an oncolytic virus and where the field is likely to head in the future.

Original language	English
Pages (from-to)	207-219
Number of pages	13
Journal	Oncolytic virotherapy
Volume	4
DOIs	https://doi.org/10.2147/OV.S66086
Publication status	Published - 2015

Bibliographical note

Copyright the Author(s) 2015. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

Keywords

herpes simplex virus
cancer
immunity
combination therapy
oncolysis

Access to Document

10.2147/OV.S66086

Publisher version (open access)Final published version, 504 KBLicence: CC BY-NC

Cite this

@article{16002ac5776a4b1f8f4900f21c8bf2ac,

title = "Oncolytic virotherapy using herpes simplex virus: how far have we come?",

abstract = "Oncolytic virotherapy exploits the properties of human viruses to naturally cause cytolysis of cancer cells. The human pathogen herpes simplex virus (HSV) has proven particularly amenable for use in oncolytic virotherapy. The relative safety of HSV coupled with extensive knowledge on how HSV interacts with the host has provided a platform for manipulating HSV to enhance the targeting and killing of human cancer cells. This has culminated in the approval of talimogene laherparepvec for the treatment of melanoma. This review focuses on the development of HSV as an oncolytic virus and where the field is likely to head in the future.",

keywords = "herpes simplex virus, cancer, immunity, combination therapy, oncolysis",

author = "Sokolowski, {Nicolas A. S.} and Helen Rizos and Diefenbach, {Russell J.}",

note = "Copyright the Author(s) 2015. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.",

year = "2015",

doi = "10.2147/OV.S66086",

language = "English",

volume = "4",

pages = "207--219",

journal = "Oncolytic virotherapy",

issn = "2253-1572",

}

TY - JOUR

T1 - Oncolytic virotherapy using herpes simplex virus

T2 - how far have we come?

AU - Sokolowski, Nicolas A. S.

AU - Rizos, Helen

AU - Diefenbach, Russell J.

N1 - Copyright the Author(s) 2015. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

PY - 2015

Y1 - 2015

N2 - Oncolytic virotherapy exploits the properties of human viruses to naturally cause cytolysis of cancer cells. The human pathogen herpes simplex virus (HSV) has proven particularly amenable for use in oncolytic virotherapy. The relative safety of HSV coupled with extensive knowledge on how HSV interacts with the host has provided a platform for manipulating HSV to enhance the targeting and killing of human cancer cells. This has culminated in the approval of talimogene laherparepvec for the treatment of melanoma. This review focuses on the development of HSV as an oncolytic virus and where the field is likely to head in the future.

AB - Oncolytic virotherapy exploits the properties of human viruses to naturally cause cytolysis of cancer cells. The human pathogen herpes simplex virus (HSV) has proven particularly amenable for use in oncolytic virotherapy. The relative safety of HSV coupled with extensive knowledge on how HSV interacts with the host has provided a platform for manipulating HSV to enhance the targeting and killing of human cancer cells. This has culminated in the approval of talimogene laherparepvec for the treatment of melanoma. This review focuses on the development of HSV as an oncolytic virus and where the field is likely to head in the future.

KW - herpes simplex virus

KW - cancer

KW - immunity

KW - combination therapy

KW - oncolysis

U2 - 10.2147/OV.S66086

DO - 10.2147/OV.S66086

M3 - Review article

C2 - 27512683

SN - 2253-1572

VL - 4

SP - 207

EP - 219

JO - Oncolytic virotherapy

JF - Oncolytic virotherapy

ER -

Oncolytic virotherapy using herpes simplex virus: how far have we come?

Abstract

Bibliographical note

Keywords

Access to Document

Fingerprint

Cite this